Literature DB >> 19380590

In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.

Emilia Cantón1, Javier Pemán, Amparo Valentín, Ana Espinel-Ingroff, Miguel Gobernado.   

Abstract

We evaluated the in vitro activities of anidulafungin, micafungin, and caspofungin against Candida krusei by determining MIC and minimum fungicidal concentration (MFC) measurements and by the time-kill method. The geometric mean (GM)-MIC/GM-MFC values were 0.1/0.34, 0.25/0.44, and 1/2.29, respectively. The mean times to reach 99.9% growth reduction were 19.1 +/- 18.2 h (mean +/- standard deviation) for 2 mg/liter anidulafungin, 37.4 +/- 8.8 h for 2 mg/liter caspofungin, and 30.7 +/- 12.2 h for 1 mg/liter micafungin. Anidulafungin exhibited the highest time-kill rate, followed by micafungin. The three echinocandins showed fungicidal activity at concentrations reached in serum.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19380590      PMCID： PMC2704671          DOI： 10.1128/AAC.00160-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death.

Authors:  A Viudes; J Pemán; E Cantón; P Ubeda; J L López-Ribot; M Gobernado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-10-31       Impact factor: 3.267

2.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  Epidemiology of candidemia.

Authors:  P Sandven
Journal:  Rev Iberoam Micol       Date:  2000-09       Impact factor: 1.044

4.  Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain.

Authors:  J Pemán; E Cantón; M Gobernado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

5.  Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.

Authors:  Cornelius J Clancy; Hong Huang; Shaoji Cheng; Hartmut Derendorf; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.

Authors:  Nita L Seibel; Cindy Schwartz; Antonio Arrieta; Patricia Flynn; Aziza Shad; Edith Albano; James Keirns; Wendi M Lau; David P Facklam; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital.

Authors:  Patricia Muñoz; Mar Sánchez-Somolinos; Luis Alcalá; Marta Rodríguez-Créixems; Teresa Peláez; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2005-01-13       Impact factor: 5.790

8.  Mechanisms of host defense against Candida species. II. Biochemical basis for the killing of Candida by mononuclear phagocytes.

Authors:  L Maródi; J R Forehand; R B Johnston
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

9.  Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.

Authors:  James A Dowell; William Knebel; Tom Ludden; Marty Stogniew; David Krause; Tim Henkel
Journal:  J Clin Pharmacol       Date:  2004-06       Impact factor: 3.126

10.  Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; E Nagy; S Dobiasova; M Rinaldi; R Barton; A Veselov
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948
View more
  8 in total

1.  Comparison of antifungal activities of gentian violet and povidone-iodine against clinical isolates of Candida species and other yeasts: a framework to establish topical disinfectant activities.

Authors:  Shigemi Kondo; Yoko Tabe; Toshihiko Yamada; Shigeki Misawa; Toyoko Oguri; Akimichi Ohsaka; Takashi Miida
Journal:  Mycopathologia       Date:  2011-08-12       Impact factor: 2.574

2.  Dose escalation studies with caspofungin against Candida glabrata.

Authors:  Marianna Domán; Renátó Kovács; David S Perlin; Gábor Kardos; Rudolf Gesztelyi; Béla Juhász; Aliz Bozó; László Majoros
Journal:  J Med Microbiol       Date:  2015-06-30       Impact factor: 2.472

3.  In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.

Authors:  Emilia Cantón; Ana Espinel-Ingroff; Javier Pemán; Lucas del Castillo
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

4.  Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum.

Authors:  Renátó Kovács; Rudolf Gesztelyi; David S Perlin; Gábor Kardos; Marianna Domán; Réka Berényi; László Majoros
Journal:  Mycopathologia       Date:  2014-08-15       Impact factor: 2.574

5.  Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates.

Authors:  Ana Espinel-Ingroff; E Canton; J Peman; E Martín-Mazuelo
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

6.  Amino acid-derived 1,2-benzisothiazolinone derivatives as novel small-molecule antifungal inhibitors: identification of potential genetic targets.

Authors:  Deepu Alex; Francoise Gay-Andrieu; Jared May; Linta Thampi; Dengfeng Dou; Aileen Mooney; William Groutas; Richard Calderone
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

7.  Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.

Authors:  Yasemin Oz; Ilknur Dag; Nuri Kiraz
Journal:  Mycopathologia       Date:  2011-08-13       Impact factor: 2.574

8.  In vitro fungicidal activities of anidulafungin, caspofungin, and micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis evaluated by time-kill studies.

Authors:  Sandra Gil-Alonso; Nerea Jauregizar; Emilia Cantón; Elena Eraso; Guillermo Quindós
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.